Revvity (NYSE:RVTY) vs. Sera Prognostics (NASDAQ:SERA) Head-To-Head Comparison

Sera Prognostics (NASDAQ:SERA) and Revvity (NYSE:RVTY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Institutional and Insider Ownership

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 13.5% of Sera Prognostics shares are owned by company insiders. Comparatively, 0.7% of Revvity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Sera Prognostics and Revvity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-34,343.16%	-41.69%	-31.77%
Revvity	8.45%	7.92%	4.81%

Valuation & Earnings

This table compares Sera Prognostics and Revvity”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80,000.00	940.88	-$32.90 million	($0.77)	-2.53
Revvity	$2.86 billion	3.57	$241.20 million	$2.08	43.88

Revvity has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Sera Prognostics and Revvity, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1	0	0	1	2.50
Revvity	0	9	5	0	2.36

Sera Prognostics presently has a consensus price target of $5.00, indicating a potential upside of 156.41%. Revvity has a consensus price target of $113.67, indicating a potential upside of 24.53%. Given Sera Prognostics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Sera Prognostics is more favorable than Revvity.

Risk & Volatility

Sera Prognostics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Revvity has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Summary

Revvity beats Sera Prognostics on 10 of the 15 factors compared between the two stocks.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

About Revvity

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.